Hypertriglyceridemic VLDL downregulates tissue plasminogen activator gene transcription through cis-repressive region(s) in the tissue plasminogen activator promoter in cultured human endothelial cells

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 20, Issue 6, 2000, Pages 1675-1681

  Tabengwa, Edlue M ^a,b   Benza, Raymond L ^a   Grenett, Hernan E ^a   Booyse, Francois M ^a  

^a University of Alabama at Birmingham   (United States)

^b NONE   (United States)

Author keywords

Cis repressive elements; Fibrinolysis; Gene regulation; Hypertriglyceridemic VLDL; Tissue plasminogen activator; Tissue plasminogen activator promoter

Indexed keywords

TISSUE PLASMINOGEN ACTIVATOR; VERY LOW DENSITY LIPOPROTEIN;

ARTICLE; BLOOD CLOTTING; CELL CULTURE; ENDOTHELIUM CELL; FIBRINOLYSIS; GENETIC REGULATION; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HYPERTRIGLYCERIDEMIA; PRIORITY JOURNAL; PROMOTER REGION; RECEPTOR BINDING; RECEPTOR DOWN REGULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSCRIPTION REGULATION;

EID: 0034041243     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.20.6.1675     Document Type: Article

References (46)

1. Hamsten A, Wiman B, de Faire V, Blomback M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med. 1985;313:1557-1563.
2. Wiman B, Hamsten A. The fibrinolytic enzyme system and its role in the etiology of thromboembolic disease. Semin Thromb Hemost. 1990;16: 207-216.
3. Raghunath PN, Tomaszewski JE, Brady ST, Caron RJ, Okada SS, Barnathan ES. Plasminogen activator system in human coronary atherosclerosis. Arterioscler Thromb Vasc Biol. 1995;15:1432-1443.
4. Li XN, Varma VK, Parks JM, Benza RL, Koons JC, Grammer JR, Grenett HE, Tabengwa EM, Booyse FM. Thrombin decreases the urokinase receptor and surface-localized fibrinolysis in cultured endothelial cells. Arterioscler Thromb Vasc Biol. 1995;15:410-419.
5. Haddock RC, Baker CD, Grammer JR, Parks JM, Speidel MT, Spell ML, Booyse FM. Urokinase binding and receptor identification in cultured endothelial cells. J Biol Chem. 1991;266:21466-21473.
6. Williams JK, Bellinger DA, Nichols TC, Griggs TR, Bumol TF, Fouts RL, Clarkson TB. Occlusive arterial thrombosis in cynomolgus monkeys with varying plasma concentrations of lipoprotein(a). Arterioscler Thromb. 1993;13:548-554.
7. Latron Y, Chautan M, Anfosso F, Alessi MC, Nalbone G, Lafont H, Juhan-Vague I. Stimulating effect of oxidized low density lipoproteins on plasminogen activator inhibitor-1 synthesis by endothelial cells. Arterioscler Thromb. 1991;11:1821-1829.
8. Kugiyama K, Sakamoto T, Misumi I, Sugiyama S, Ohgushi M, Ogawa H, Horiguchi M, Yasue H. Transferable lipids in oxidized low-density lipoprotein stimulate plasminogen activator inhibitor-1 and inhibit tissue-type plasminogen activator release from endothelial cells. Circ Res. 1993;73:335-343.
9. Tremoli E, Camera M, Maderna P, Sironi L, Prati L, Colli S, Piovella F, Bernini F, Corsini A, Mussoni L. Increased synthesis of plasminogen activator inhibitor-1 by cultured human endothelial cells exposed to native and modified LDLs: an LDL receptor-independent phenomenon. Arterioscler Thromb. 1993;13:338-346.
10. Levin EG, Miles LA, Fless GM, Scanu AM, Baynham P, Curtiss LK, Plow EF. Lipoproteins inhibit the secretion of tissue plasminogen activator from human endothelial cells. Arterioscler Thromb. 1994;14: 438-442.
11. Stiko-Rahm A, Wiman B, Hamsten A, Nilsson J. Secretion of plasminogen activator inhibitor-1 from cultured human umbilical vein endothelial cells is induced by very low density lipoproteins. Arteriosclerosis. 1990; 10:1067-1073.
12. Mussoni L, Mannucci L, Sirtori M, Camera M, Madema P, Sironi L, Tremoli E. Hypertriglyceridemia and regulation of fibrinolytic activity. Arterioscler Thromb. 1992;12:19-27.
13. Li XN, Koons JC, Benza RL, Parks JM, Varma VK, Bradley WA, Gianturco SH, Taylor KB, Grammer JR, Tabengwa EM, Booyse FM. Hypertriglyceridemic VLDL decreases plasminogen binding to endothelial cells and surface-localized fibrinolysis. Biochemistry. 1996;35: 6080-6088.
14. Li XN, Grenett HE, Benza RL, Bradley WA, Gianturco SH, Grammer JR, Tabengwa EM, Gay CP, Booyse FM. Genotype-specific regulation of PAI-1 expression by hypertriglyccridcmic VLDL in PAI-1 genotyped cultured human endothelial cell types. Circulation. 1995;92(suppl I):I-694. Abstract.
15. f 100-400 hypertriglyceridemic very low density lipoproteins by the low density lipoprotein receptor pathway in normal human fibroblasts. J Biol Chem. 1983;258:4526-4533.
16. Juhan-Vague I, Alessi MC. Plasminogen activator inhibitor 1 and atherothrombosis. Thromb Haemost. 1993;70:138-143.
17. Padro T, Emeis JJ, Steins M, Schmid KW, Kienast J. Quantification of plasminogen activators and their inhibitors in the aortic vessel wall in relation to the presence and severity of atherosclerotic disease. Arterioscler Thromb Vasc Biol. 1995;15:893-902.
18. Reilly JM, Sicard GA, Lucore CL. Abnormal expression of plasminogen activators in aortic aneurysmal and occlusive disease. J Vasc Surg. 1994; 19:865-872.
19. Hayakawa Y, Tazawa S, Ishikawa T, Niiya K, Sakuragawa N. Transcriptional regulation of tissue- and urokinase-type plasminogen activator genes by thrombin in human fetal lung fibroblasts. Thromb Haemost. 1995;74:704-710.
20. Medcalf RL, Ruegg M, Schleuning WD. A DNA motif related to the cAMP-responsive element and an exon-located activator protein-2 binding site in the human tissue-type plasminogen activator gene promoter cooperate in basal expression and convey activation by phorbol ester and cAMP. J Biol Chem. 1990;265:14618-14626.
21. Grenett HE, Torres JA, Demissie S, Tabengwa EM, Davis GC, Booyse FM. Ethanol transcriptionally upregulates t-PA and u-PA gene expression in cultured human endothelial cells. Alcohol Clin Exp Res. 1998;22: 849-853.
22. Medcalf RL, Schleuning WD. Regulation of human tissue-type plasminogen activator gene transcription by epidermal growth factor and 3′,5′-cyclic adenosine monophosphate. Mol Endocrinol. 1991;5:1773-1779.
23. Maciag T, Cerundolo J, Ilsley S, Kelley PR, Forand R. An endothelial cell growth factor from bovine hypothalamus: identification and partial characterization. Proc Natl Acad Sci U S A. 1979;76:5674-5678.
24. Gianturco SH, Bradley WA. The role of apolipoprotein processing in receptor recognition of VLDL. In: Albers JJ, Segrest JP, eds. Methods in Enzymology. New York, NY: Academic Press; 1986:319-344.
25. Fredrickson DS, Goldstein JL, Brown MS. The familial hyperlipoproteinemias. In: Stanbury JG, Wyngaarden MF., Fredrickson DS, eds. The Metabolic Basis of Inherited Diseases. New York, NY: McGraw-Hill; 1978:604-655.
26. Lindgren FT, Jensen LC, Hatch FT. The isolation and quantitative analysis of serum lipoproteins in blood lipids and lipoproteins. In: Nelson GJ, ed. Blood Lipids and Lipoproteins. New York, NY: Wiley Interscience; 1972:181-274.
27. Gianturco SH, Ramprasad MP, Lin A, Song R, Bradley WA. Cellular binding site and membrane binding proteins for triglyceride-rich lipoproteins in human monocyte-macrophages and THP-1 monocytic cells. J Lipid Res. 1994;35:1674-1687.
28. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951;193:265-275.
29. Li XN, Grenett HE, Benza RL, Demissie S, Brown SL, Tabengwa EM, Bradley WA, Gianturco SH, Fless GM, Booyse FM. Genotype-specific transcriptional regulation of PAI-1 expression by hypertriglyceridemic (HTG)-VLDL and Lp(a) in cultured human endothelial cells. Arterioscler Thromb Vasc Biol. 1997;17:3215-3223.
30. Booyse FM, Quarfoot AJ, Chediak J, Stemerman MB, Maciag T. Characterization and properties of cultured human von Willebrand umbilical vein endothelial cells. Blood. 1981;58:788-796.
31. Voyta JC, Via DP, Butterfield CE, Zetter BR. Identification and isolation of endothelial cells based on their increased uptake of acetylated-low density lipoprotein. J Cell Biol. 1984;99:2034-2040.
32. Jaffe EA, Nachman RL, Becker CG, Minick CR. Culture of human endothelial cells derived from umbilical veins: identification by morphologic and immunologic criteria. J Clin Invest. 1973;52:2745-2756.
33. Degen SJF, Rajput B, Reich E. The human tissue plasminogen activator gene. J Biol Chem. 1986;261:6972-6985.
34. Tso JY, Sun X, Kao T, Reece KS, Wu R. Isolation and characterization of rat and human glyceraldehyde-3-phosphate dehydrogenase cDNAs: genomic complexity and molecular evolution of the gene. Nucleic Acids Res. 1985;13:2485-2502.
35. Mussoni L, Lawrence D, Loskutoff DJ. A direct, plasmin-independent assay for plasminogen activator. Thromb Res. 1984;34:241-254.
36. Booyse FM, Scheinbuks J, Lin P, Traylor M, Bruce R. Isolation and interrelationships of the multiple molecular tissue-type and urokinase-type plasminogen activator forms produced by cultured human umbilical vein endothelial cells. J Biol Chem. 1988;263:15129-15138.
37. Laemmili UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970;227:680-685.
38. Greenberg ME, Ziff EB. Stimulation of 3T3 cells induces transcription of the c-fos proto-oncogene. Nature. 1984;311:433-438.
39. Grenett HE, Benza RL, Fless GM, Li XN, Davis GC, Booyse FM. Genotype-specific transcriptional regulation of PAI-1 gene expression by insulin, hypertriglyceridemic VLDL, and Lp(a) in transfected cultured human endothelial cells. Arterioscler Thromb Vasc Biol. 1998;18: 1803-1809.
40. Maniatis T, Fritsch EF, Sambrook J. Plasmid vectors. In: Irwin N, Ford N, Nolan C, Ferguson M, Ockler M, eds. Molecular Cloning: A Laboratory Manual. 2nd ed. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory; 1982:1.38-1.39.
41. Lorenz WW, Cormier MJ, O'Kane DJ, Hua D, Escher AA, Szalay AA. Expression of the Renilla reniformis luciferase gene in mammalian cells. J Biolumin Chemilumin. 1996;11:31-37.
42. Farr A, Roman A. A pitfall of using a second plasmid to determine transfection efficiency. Nucleic Acids Res. 1992;20:920.
43. Pekalharing HL, Kleinveld HA, Duif PF, Bouma BN, van Rijn HJ. Effect of lipoprotein(a) and LDL on plasminogen binding to extracellular matrix and on matrix-dependent plasminogen activation by tissue plasminogen activator. Thromb Haemost. 1996;75:497-502.
44. Eriksson P, Nilsson L, Karpe F, Hamsten A. Very-low-density lipoprotein response element in the promoter region of the human plasminogen activator inhibitor-1 gene implicated in the impaired fibrinolysis of hypertriglyceridemia. Arterioscler Thromb Vasc Biol. 1998;18:20-26.
45. De Cesare D, Vallone D, Caracciolo A, Sassone-Corsi P, Nerlov C, Verde P. Heterodimerization of c-Jun with ATF-2 and c-Fos is required for positive and negative regulation of the human urokinase enhancer. Oncogene. 1995;11:365-376.
46. Nerlov D, De Cesare D, Pergola F, Caracciolo A, Blasi F, Johnsen M, Verde P. A regulatory element that mediates co-operation between a PEA3-AP-1 element and an AP-1 site is required for phorbol ester induction of urokinase enhancer activity in HepG2 hepatoma cells. EMBO J. 1992;11:4573-4582.